Drugs / Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine
Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06621654 | Nov 2024 → Oct 2026 expected | haemophilus infectious disease | CanSino Biologics Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06621654 ↗ |
| Modality | Vaccine | “Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine” NCT06621654 ↗ |